Explore

Communities in English

Advertise on Engormix

Multi-aspect safety assessment of bacteriophage products dedicated for animal health

Published: January 31, 2023
By: Ewelina Wójcik and Jaroslaw Dastych.
Multi-aspect safety assessment of bacteriophage products dedicated for animal health - Image 1
During July 18th - 22nd our Research & Development team participated in the 6th Viruses of Microbes conference, which took place in Guimarães, Portugal. Our colleague Ewelina Wójcik presented the results of one of the recently conducted studies on Multi-aspect safety assessment of bacteriophage products dedicated for animal health.
Developing a modern phage commercial product requires selecting appropriate cocktail components and choosing the right product format that supports effective delivery of active phages to the targeted site. Proteon Pharmaceuticals created the innovative technology platform that allows to successfully develop phage-based products and implement new strategies allowing to control pathogenic bacteria which affect animal production industry. Proteon's platform allows to design highly effective products consisting of a mixture of carefully selected and genotypically characterized virulent phages that eliminate pathogenic bacteria, without causing side effects, while improving performance on the farm. 
Multi-aspect safety assessment of bacteriophage products dedicated for animal health
Proteon’s flagship product BAFASAL® is a feed additive for industrial poultry sector protecting birds against Salmonella. The preparation was examined in line with the EFSA guidelines proving its high safety for human, birds, and environment. 
Moreover, multiple studies confirmed high effectiveness in reducing Salmonella in birds and in the environment of poultry production sites. 
While phages have an excellent safety profile, employing phage products on a large scale in the food production sector is perceived as a novel technological approach. Bacteriophages used in the industry can make their way into humans through food chain or exposure. A broad acceptance of the phage technology might require an additional effort to better understand potential effects of their introduction into food chain and work environment.
Multi-aspect safety assessment of bacteriophage products dedicated for animal health
Proteon, together with MedBiome Inc., applied an in vitro assay called RapidAIM to investigate the effect of BAFASAL® on human gut microbiome. RapidAIM (rapid assay of an individual microbiome) measures compositional and functional changes in the gut microbiome in response to dietary and therapeutic interventions, therefore it can be used to estimate the impact of products on the microbiota. In this study, we investigated whether BAFASAL® phage introduction to the human microbiome affects its composition and function. We treated five individual adult-derived gut microbiomes with active and inactive mixtures of BAFASAL®. This study, the first of its kind, has important implications for how we measure food safety and maintain the safety of workers in the food-processing industry exposed to these preparations.
The conclusion:
Multi-omics analyses, including 16S rRNA gene sequencing and metaproteomic, revealed that ex vivo human gut microbiota composition and function were unaffected by BAFASAL® treatment, providing an additional measure for its safety.
Related topics:
Authors:
Jaroslaw Dastych
Proteon Pharmaceuticals
Influencers who recommended :
Dr. Varun Namdeo
Recommend
Comment
Share
Profile picture
Would you like to discuss another topic? Create a new post to engage with experts in the community.
Featured users in Poultry Industry
Annie Kneedler
Annie Kneedler
Cargill
United States
Kendra Waldbusser
Kendra Waldbusser
Pilgrim´s
United States
Thu Dinh
Thu Dinh
Tyson
Tyson
United States
Join Engormix and be part of the largest agribusiness social network in the world.